TOLISCRIN® 1
(Sodium Colistimethate 1M IU)

TOLISCRIN® 2
(Sodium Colistimethate 2M IU)

TOLISCRIN® 100
Colistin (as sodium methansulphonate equivalent to base) 100 mg

Sterile Powder
Injection Solution or Inhalation Solution
Argentine Industry - Dispense under prescription

 

Composition:

Each TOLISCRIN® 1 glass bottle contains: 
Sodium colistimethate  1M IU
Disolvent ampoule: non-pyrogenic distilled water 2.00 ml

Each TOLISCRIN® 2 glass bottle contans: 
Sodium colistimethate 2M IU
Disolvent ampoule: non-pyrogenic distilled water  2.00 ml

Each TOLISCRIN® 100 glass bottle contains: 
Colistin (as sodium metansulphonate equivalent to base) 100
Ampolla disolvente: Agua destilada apirógena 2.00ml

Therapeutic action:

Antibacterial; antibiotic belonging to the polymyxin group derived from Bacillus polymyxa var. colistinus. Polypeptide antibiotic with action against Gram-negative aerobic bacteria.

Indications:

TOLISCRIN® is indicated for the treatment of the following infections where the sensitive testing suggests that they are caused by susceptible bacteria:

Treatment by inhalation of the Pseudomonas aeruginosa lung infection in patients with cyctic fibrosis (CF).

Intravenous administration for the treatment of some serious infections caused by Gram-negative bacteria, including infections of the lower respiratory tract and urinary tract, when systemic antibacterial agents are contraindicated or may be ineffective because of bacterial resistance.

Mode of action:

Sodium colistimethate is a cyclic polypeptide antibiotic derived from Bacillus polymyxa var. colistinus and belongs to the polymyxin group. The polymyxin antibiotic are cationic agents that work by damaging the cell membrane. The resulting physiological effects are lethtal to the bacterium. Polymyxins are Gram-negative bacteria that have an hydrophobic outer membrane.

Dose and administration:

Systemic treatment

TOLISCRIN®, the active ingredient of which is sodium colistimethate, can be administrated as a 50-ml intravenous infusión over a period of 30 minutes. Patients with a totally implantable venous access device (TIVAD) in place may tolérate a bolus injection of up to 2 million units in 10 ml administered over not less tan 5 minutes.

For the treatment of local infections of the lower respiratory tract, TOLISCRIN® sterile poder shouldbe disolved in 2 - 4 ml of water for injections or in intravenous infusion of 0.9% sodium chloride to be used in nebuliser conected to an air-oxigen inlet.
In reduced, non-controlled clinical trials, the 500000 unit dose administered twice a day were resulted safe and effective in patients with cystic fibrosis.

The following doses constitute a guide and should be adjusted according to the clinical response:

Children <2 years: 500000 a 1000000 units twice a day
Children >2 years and adults: 1000000 a 2000000 units twice a day
Storage: Store at room temperature (below 30°C). Keep the product in the marketed packing.

How Supplied:

TOLISCRIN® 1:
Pack containing 1 glass bottle with sterile powder + 1 glass bottle with sterile distilled water.
Pack containing 4 glass bottles with sterile powder + 4 glass bottles with sterile distilled water.
Pack containing 30 glass bottles with sterile powder + 30 glass bottles with sterile distilled water.

TOLISCRIN® 2:
Pack containing 1 glass bottle with sterile powder + 1 glass bottle with sterile distilled water.
Pack containing 4 glass bottles with sterile powder + 4 glass bottles with sterile distilled water.
Pack containing 30 glass bottles with sterile powder + 30 glass bottles with sterile distilled water.

TOLISCRIN® 100:
Pack containing 1 glass bottle with sterile powder + 1 glass bottle with sterile distilled water.
Pack containing 4 glass bottles with sterile powder + 4 glass bottles with sterile distilled water.
Pack containing 30 glass bottles with sterile powder + 30 glass bottles with sterile distilled water.

Medicinal speciality authorised by the Ministry of Health 
Certificate No. 55633

Laboratorio DOSA S.A.
Girardot 1369 (C1427AKC)  Buenos Aires, Argentine Republic.
Pharmaceutical Director: María Cecilia Terzo, Pharmacist.